The company attributes the better numbers to all-around improvement in sales of its products, especially that from its so-called speciality pharma principals segment, which has rebounded from supply chain woes in 1HFY2023.
In addition, the introduction of new products from the likes of Laboratoires Gilbert in this segment helped drive sales too, the company adds.
Hyphens Pharma sells its proprietary products as well. The slight revenue dip for this segment was attributed to its channel partners stocking up in the preceding 4QFY2023.
Besides boosting sales, the company plans to build long-term growth with acquisitions.
See also: Keppel Pacific Oak US REIT’s 1QFY2025 distributable income falls by 19.3% y-o-y to US$9.6 mil
Hyphens Pharma shares closed at 27 cents on May 14, down 1.85% for the day and down 5.36% year to date.
